Rukobia
Gilead bags first approval for twice-yearly HIV therapy
Phil Taylor
Gilead Sciences, HIV, lenacapavir, regulatory approval, Rukobia, Sunlenca, ViiV Healthcare
0 Comment
X
Gilead bags first approval for twice-yearly HIV therapy
https://pharmaphorum.com/news/gilead-bags-first-approval-for-twice-yearly-hiv-therapy/
Gilead tries again with twice-yearly HIV drug lenacapavir
Phil Taylor
follicular lymphoma, Gilead Sciences, HIV, infectious disease, lenacapavir, Oncology, Rukobia, ViiV Healthcare, Yescarta
0 Comment
X
Gilead tries again with twice-yearly HIV drug lenacapavir
https://pharmaphorum.com/news/gilead-tries-again-with-twice-yearly-hiv-drug-lenacapavir/
Gilead challenges ViiV in resistant HIV, filing twice-yearly therapy
Phil Taylor
Gilead Sciences, HIV, infectious disease, lenacapavir, Rukobia, ViiV Healthcare
0 Comment
X
Gilead challenges ViiV in resistant HIV, filing twice-yearly therapy
https://pharmaphorum.com/news/gilead-challenges-viiv-in-resistant-hiv-filing-twice-yearly-therapy/